Cellular-FLICE inhibitory protein (c-FLIP) is a key anti-apoptotic regulator that inhibits cell
death mediated by the death receptors Fas, DR4, DR5, and TNF-R1. Three splice variants of …

Cancer of the urinary bladder is the second most common malignancy of the genitourinary
tract, currently accounting for up to 5% of all newly diagnosed tumours in the western world …

The mitogen-activated protein kinase (MAPK)/extracellular signal kinase (ERK) and
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signal transduction pathways …

Background Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, has
recently shown antitumor activity in various cancer cells. Apo2 ligand or tumor necrosis …

Doxorubicin (DOX) is an anthracycline antibiotic that is widely used to treat different types of
malignancy. In this study, it was studied whether DOX could be used to render tumor cells …

Bladder cancer is a therapeutically challenging disease and wealth of knowledge has
enabled researchers to develop a clear understanding of mechanisms which underlie …

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), either alone or in
combination with other anti-cancer agents, has been considered as a new strategy for anti …

The exact molecular mechanism underlying the heterogeneous drug response against
breast carcinoma remains to be fully understood. It is urgently required to identify key genes …

Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a death receptor ligand
that has the ability to preferentially initiate apoptosis in malignant cells with minimal toxicity …

Urothelial carcinoma of the bladder accounts for∼ 5% of all cancer deaths in humans. The
majority of bladder tumors are non-muscle invasive at diagnosis, and there is a high rate of …